<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33443670</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>14</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1590-3478</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><Issue>3</Issue><PubDate><Year>2021</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology</Title><ISOAbbreviation>Neurol Sci</ISOAbbreviation></Journal><ArticleTitle>Multidisciplinary care in Amyotrophic Lateral Sclerosis: a systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>911</StartPage><EndPage>923</EndPage><MedlinePgn>911-923</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10072-020-05011-2</ELocationID><Abstract><AbstractText>Multidisciplinary care (MDC) has been the most recommended approach for symptom management in amyotrophic lateral sclerosis (ALS) but there is conflicting evidence about its effectiveness on survival and quality of life (QoL) of ALS patients. We conducted a systematic review to determine the effects of multidisciplinary care compared to general neurological care in survival and quality of life of ALS patients. A comprehensive literature search using Scopus, MEDLINE-PubMed, Cochrane, Web of Science, PEDro, and Science Direct was undertaken. Studies related to multidisciplinary care or general neurological care in ALS patients that assessed survival and quality of life and were published in the period up to and including January 2020 were included. A total of 1192 studies were initially identified, but only 6 were included. All studies that investigated survival showed and advantage of MDC over NC, and this benefit was even greater for bulbar onset patients. A meta-analysis was performed and showed a mean difference of 141.67 (CI 95%, 61.48 to 221.86), indicating that patients who received MDC had longer survival than those who underwent NC (p = 0.0005). Concerning QoL, only one study found better mental health scores related to QoL for patients under MDC. Multidisciplinary care is more effective than general neurology care at improving survival of patients with ALS, but only improves mental health outcomes related to quality of life of these patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>de Almeida</LastName><ForeName>Filipe Emanuel Oliveira</ForeName><Initials>FEO</Initials><AffiliationInfo><Affiliation>Sergipe University Hospital of Universidade Federal de Sergipe-UFS, Aracaju, SE, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>do Carmo Santana</LastName><ForeName>Anne Kelly</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>Sergipe University Hospital of Universidade Federal de Sergipe-UFS, Aracaju, SE, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Carvalho</LastName><ForeName>Fernanda Oliveira</ForeName><Initials>FO</Initials><Identifier Source="ORCID">0000-0002-1270-406X</Identifier><AffiliationInfo><Affiliation>Sergipe University Hospital of Universidade Federal de Sergipe-UFS, Aracaju, SE, Brazil. fsoliveira.fisio@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Health Sciences Graduate Center of Universidade Federal de Sergipe-UFS, S&#xe3;o Crist&#xf3;v&#xe3;o, SE, 49100-000, Brazil. fsoliveira.fisio@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>01</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Neurol Sci</MedlineTA><NlmUniqueID>100959175</NlmUniqueID><ISSNLinking>1590-1874</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058025" MajorTopicYN="N">Interdisciplinary Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010166" MajorTopicYN="N">Palliative Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Meta-analysis</Keyword><Keyword MajorTopicYN="N">Multidisciplinary care</Keyword><Keyword MajorTopicYN="N">Quality of life</Keyword><Keyword MajorTopicYN="N">Survival</Keyword><Keyword MajorTopicYN="N">Systematic review</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>9</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>12</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>1</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>1</Month><Day>14</Day><Hour>12</Hour><Minute>11</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33443670</ArticleId><ArticleId IdType="doi">10.1007/s10072-020-05011-2</ArticleId><ArticleId IdType="pii">10.1007/s10072-020-05011-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardiman O, Al-Chalabi A, Chio A et al (2017) Amyotrophic lateral sclerosis. Nat Rev Dis Prim 3:1&#x2013;19. https://doi.org/10.1038/nrdp.2017.71</Citation></Reference><Reference><Citation>Wobst HJ, Mack KL, Brown DG, Brandon NJ, Shorter J (2020) The clinical trial landscape in amyotrophic lateral sclerosis&#x2014;past, present, and future. Med Res Rev 40:1352&#x2013;1384</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/med.21661</ArticleId></ArticleIdList></Reference><Reference><Citation>Logroscino G, Piccininni M (2019) Neuroepidemiology of aging-review amyotrophic lateral sclerosis descriptive epidemiology: the origin of geographic difference keywords amyotrophic lateral sclerosis Population-based study &#xb7; cohort &#xb7; registries &#xb7; Global Burden of Disease &#xb7; C9ORF72 &#xb7; Incidence &#xb7; Ancestry &#xb7; Ethnicity &#xb7; Geographic gradient. https://doi.org/10.1159/000493386</Citation></Reference><Reference><Citation>Longinetti E, Fang F (2019) Epidemiology of amyotrophic lateral sclerosis: An update of recent literature. Curr Opin Neurol 32:771&#x2013;776. https://doi.org/10.1097/WCO.0000000000000730</Citation></Reference><Reference><Citation>Dorst J, Chen L, Rosenbohm A, Dreyhaupt J, H&#xfc;bers A, Schuster J, Weishaupt JH, Kassubek J, Gess B, Meyer T, Weyen U, Hermann A, Winkler J, Grehl T, Hagenacker T, Lingor P, Koch JC, Sperfeld A, Petri S, Gro&#xdf;kreutz J, Metelmann M, Wolf J, Winkler AS, Klopstock T, Boentert M, Johannesen S, Storch A, Schrank B, Zeller D, Liu XL, Tang L, Fan DS, Ludolph AC (2019) Prognostic factors in ALS: a comparison between Germany and China. J Neurol 266:1516&#x2013;1525. https://doi.org/10.1007/s00415-019-09290-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-019-09290-4</ArticleId><ArticleId IdType="pubmed">30923935</ArticleId></ArticleIdList></Reference><Reference><Citation>Jun KY, Park J, Oh KW, Kim EM, Bae JS, Kim I, Kim SH (2019) Epidemiology of ALS in Korea using nationwide big data. J Neurol Neurosurg Psychiatry 90:395&#x2013;403. https://doi.org/10.1136/jnnp-2018-318974</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-318974</ArticleId><ArticleId IdType="pubmed">30409890</ArticleId></ArticleIdList></Reference><Reference><Citation>The WHOQOL group (1995) The World Health Organization quality of life assessment (WHOQOL): Position paper from the World Health Organization. Soc Sci Med 41:1403&#x2013;1409. https://doi.org/10.1016/0277-9536(95)00112-K</Citation></Reference><Reference><Citation>Simmons Z (2015) Patient-Perceived Outcomes and Quality of Life in ALS. Neurotherapeutics 12:394&#x2013;402. https://doi.org/10.1007/s13311-014-0322-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-014-0322-x</ArticleId><ArticleId IdType="pubmed">25502407</ArticleId></ArticleIdList></Reference><Reference><Citation>Maessen M, Veldink JH, Onwuteaka-Philipsen BD, de Vries JM, Wokke JHJ, van der Wal G, van den Berg LH (2009) Trends and determinants of end-of-life practices in ALS in the Netherlands. Neurology 73:954&#x2013;961. https://doi.org/10.1212/WNL.0b013e3181b87983</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181b87983</ArticleId><ArticleId IdType="pubmed">19770471</ArticleId></ArticleIdList></Reference><Reference><Citation>Craig A, Dzeng E (2018) How should physicians care for dying patients with amyotrophic lateral sclerosis? AMA J Ethics 20:690&#x2013;698. https://doi.org/10.1001/amajethics.2018.690</Citation></Reference><Reference><Citation>Andersen PM, Abrahams S, Borasio GD et al (2012) EFNS guidelines on the Clinical Management of Amyotrophic Lateral Sclerosis (MALS) - revised report of an EFNS task force. Eur J Neurol 19:360&#x2013;375. https://doi.org/10.1111/j.1468-1331.2011.03501.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2011.03501.x</ArticleId><ArticleId IdType="pubmed">21914052</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogden A, Foley G, Henderson RD, James N, Aoun S (2017) Amyotrophic lateral sclerosis: improving care with a multidisciplinary approach. J Multidiscip Healthc 10:205&#x2013;215</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/JMDH.S134992</ArticleId></ArticleIdList></Reference><Reference><Citation>De Carvalho M, Gooch CL (2017) The yin and yang of gastrostomy in the management of ALS. Neurology 89:1435&#x2013;1436</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004547</ArticleId></ArticleIdList></Reference><Reference><Citation>Dharmadasa T, Kiernan MC (2018) Riluzole, disease stage and survival in ALS. Lancet Neurol 17:385&#x2013;386</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30091-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorst J, Ludolph AC (2019) Non-invasive ventilation in amyotrophic lateral sclerosis. Ther Adv Neurol Disord 12:1756286419857040</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1756286419857040</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Bottacchi E, Buffa C, Mutani R, Mora G, PARALS (2006) Positive effects of tertiary centres for amyotrophic lateral sclerosis on outcome and use of hospital facilities. J Neurol Neurosurg Psychiatry 77:948&#x2013;950. https://doi.org/10.1136/jnnp.2005.083402</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2005.083402</ArticleId><ArticleId IdType="pubmed">16614011</ArticleId><ArticleId IdType="pmc">2077622</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Jackson CE, Kasarskis EJ et al (2009) Practice Parameter update: the care of the patient with amyotrophic lateral sclerosis: Multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 73:1227&#x2013;1233. https://doi.org/10.1212/WNL.0b013e3181bc01a4</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181bc01a4</ArticleId><ArticleId IdType="pubmed">19822873</ArticleId><ArticleId IdType="pmc">2764728</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin S, Trevor-Jones E, Khan S, Shaw K, Marchment D, Kulka A, Ellis CE, Burman R, Turner MR, Carroll L, Mursaleen L, Leigh PN, Shaw CE, Pearce N, Stahl D, al-Chalabi A (2017) The benefit of evolving multidisciplinary care in ALS: a diagnostic cohort survival comparison. Amyotroph Lateral Scler Front Degener 18:569&#x2013;575. https://doi.org/10.1080/21678421.2017.1349151</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1349151</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoccolella S, Beghi E, Palagano G, Fraddosio A, Guerra V, Lepore V, Simone IL, Lamberti P, Serlenga L, Logroscino G (2007) ALS multidisciplinary clinic and survival: Results from a population-based study in Southern Italy. J Neurol 254:1107&#x2013;1112. https://doi.org/10.1007/s00415-006-0401-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-006-0401-y</ArticleId><ArticleId IdType="pubmed">17431705</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng L, Khan F, Mathers S (2009) Multidisciplinary care for adults with amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database Syst Rev (4):CD007425. https://doi.org/10.1002/14651858.CD007425.pub2</Citation></Reference><Reference><Citation>Ng L, Khan F, Young CA, Galea M (2017) Symptomatic treatments for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev (1):011776. https://doi.org/10.1002/14651858.CD011776.pub2</Citation></Reference><Reference><Citation>Loney PL, Chambers LW, Bennett KJ, Roberts JG, Stratford PW (1998) Critical appraisal of the health research literature: prevalence or incidence of a health problem. Chronic Dis Can 19:170&#x2013;176</Citation><ArticleIdList><ArticleId IdType="pubmed">10029513</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartling L, Hamm M, Milne A et al (2012) Validity and Inter-Rater Reliability Testing of Quality Assessment Instruments. Agency for Healthcare Research and Quality, Rockville (US)</Citation></Reference><Reference><Citation>Higgins JPT, Altman DG, G&#xf8;tzsche PC et al (2011) The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 343:343. https://doi.org/10.1136/bmj.d5928</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.d5928</ArticleId></ArticleIdList></Reference><Reference><Citation>The Nordic Cochrane Centre (2014) Review manager (RevMan). Cochrane Collaboration, Copenhagen</Citation></Reference><Reference><Citation>Garc&#xed;a IJ, Moya NS, Munt MR et al (2015) La opini&#xf3;n del paciente cuenta: experiencia en la atenci&#xf3;n nutricional en un equipo multidisciplinar de ELA. Nutr Hosp 31:56&#x2013;66. https://doi.org/10.3305/nh.2015.31.sup5.9132</Citation><ArticleIdList><ArticleId IdType="doi">10.3305/nh.2015.31.sup5.9132</ArticleId></ArticleIdList></Reference><Reference><Citation>Paipa AJ, Povedano M, Barcelo A et al (2019) Survival benefit of multidisciplinary care in amyotrophic lateral sclerosis in spain: association with noninvasive mechanical ventilation. J Multidiscip Healthc 12:465&#x2013;470. https://doi.org/10.2147/JMDH.S205313</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/JMDH.S205313</ArticleId><ArticleId IdType="pubmed">31354285</ArticleId><ArticleId IdType="pmc">6590410</ArticleId></ArticleIdList></Reference><Reference><Citation>Traynor BJ, Alexander M, Corr B, Frost E, Hardiman O (2003) Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: A population based study, 1996-2000. J Neurol Neurosurg Psychiatry 74:1258&#x2013;1261. https://doi.org/10.1136/jnnp.74.9.1258</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.74.9.1258</ArticleId><ArticleId IdType="pubmed">12933930</ArticleId><ArticleId IdType="pmc">1738639</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephens HE, Felgoise S, Young J, Simmons Z (2015) Multidisciplinary ALS clinics in the USA: a comparison of those who attend and those who do not. Amyotroph Lateral Scler Front Degener 16:196&#x2013;201. https://doi.org/10.3109/21678421.2014.994530</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.994530</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Den Berg JP, Kalmijn S, Lindeman E et al (2005) Multidisciplinary ALS care improves quality of life in patients with ALS. Neurology 65:1264&#x2013;1267. https://doi.org/10.1212/01.wnl.0000180717.29273.12</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000180717.29273.12</ArticleId><ArticleId IdType="pubmed">16247055</ArticleId></ArticleIdList></Reference><Reference><Citation>Rooney J, Byrne S, Heverin M, Tobin K, Dick A, Donaghy C, Hardiman O (2015) A multidisciplinary clinic approach improves survival in ALS: a comparative study of ALS in Ireland and Northern Ireland. J Neurol Neurosurg Psychiatry 86:496&#x2013;501</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2014-309601</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenkins TM, Hollinger H, McDermott CJ (2014) The evidence for symptomatic treatments in amyotrophic lateral sclerosis. Curr Opin Neurol 27:524&#x2013;531</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000135</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriani MH, Desnuelle C (2017) Care management in amyotrophic lateral sclerosis. Rev Neurol (Paris) 173:288&#x2013;299</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurol.2017.03.031</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei Q, Chen X, Zheng Z, Guo X, Huang R, Cao B, Zeng Y, Shang H (2015) The predictors of survival in Chinese amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Front Degener 16:237&#x2013;244. https://doi.org/10.3109/21678421.2014.993650</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.993650</ArticleId></ArticleIdList></Reference><Reference><Citation>Burkhardt C, Neuwirth C, Sommacal A et al (2017) Is survival improved by the use of NIV and PEG in amyotrophic lateral sclerosis (ALS)? A post-mortem study of 80 ALS patients. PLoS One:12. https://doi.org/10.1371/journal.pone.0177555</Citation></Reference><Reference><Citation>Mandrioli J, Malerba SA, Beghi E et al (2018) Riluzole and other prognostic factors in ALS: a population-based registry study in Italy. J Neurol 265:817&#x2013;827. https://doi.org/10.1007/s00415-018-8778-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-018-8778-y</ArticleId><ArticleId IdType="pubmed">29404735</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Nicholson K, Leigh F, Swoboda K, Chad D, Drake K, Haley K, Cudkowicz M, Berry JD (2017) Developing multidisciplinary clinics for neuromuscular care and research. Muscle Nerve 56:848&#x2013;858. https://doi.org/10.1002/mus.25725</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.25725</ArticleId><ArticleId IdType="pubmed">28632945</ArticleId><ArticleId IdType="pmc">5656914</ArticleId></ArticleIdList></Reference><Reference><Citation>Young CA, Ealing J, McDermott C, Williams T, al-Chalabi A, Majeed T, Burke G, Pinto A, Dick D, Talbot K, Harrower T, Walsh J, Chandran S, Hanemann CO, Mills R, Tennant A (2019) The relationships between symptoms, disability, perceived health and quality of life in amyotrophic lateral sclerosis/motor neuron disease. Amyotroph Lateral Scler Front Degener 20:317&#x2013;327. https://doi.org/10.1080/21678421.2019.1615951</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1615951</ArticleId></ArticleIdList></Reference><Reference><Citation>Hobson EV, McDermott CJ (2016) Supportive and symptomatic management of amyotrophic lateral sclerosis. Nat Rev Neurol 12:526&#x2013;538</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2016.111</ArticleId></ArticleIdList></Reference><Reference><Citation>Oskarsson B, Gendron TF, Staff NP (2018) Amyotrophic lateral sclerosis: an update for 2018. Mayo Clin Proc 93:1617&#x2013;1628</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocp.2018.04.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Rooney J, Byrne S, Heverin M, Corr B, Elamin M, Staines A, Goldacre B, Hardiman O (2013) Survival analysis of irish amyotrophic lateral sclerosis patients diagnosed from 1995&#x2013;2010. PLoS One 8:e74733. https://doi.org/10.1371/journal.pone.0074733</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0074733</ArticleId><ArticleId IdType="pubmed">24098664</ArticleId><ArticleId IdType="pmc">3786977</ArticleId></ArticleIdList></Reference><Reference><Citation>Westeneng H-J, Debray TPA, Visser AE et al (2018) Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol 17:423&#x2013;433. https://doi.org/10.1016/S1474-4422(18)30089-9</Citation></Reference><Reference><Citation>Ong ML, Tan PF, Holbrook JD (2017) Predicting functional decline and survival in amyotrophic lateral sclerosis. PLoS One 12:e0174925. https://doi.org/10.1371/journal.pone.0174925</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0174925</ArticleId><ArticleId IdType="pubmed">28406915</ArticleId><ArticleId IdType="pmc">5390993</ArticleId></ArticleIdList></Reference><Reference><Citation>Ralli M, Lambiase A, Artico M, de Vincentiis M, Greco A (2019) Amyotrophic lateral sclerosis: autoimmune pathogenic mechanisms, clinical features, and therapeutic perspectives. Isr Med Assoc J 21:438&#x2013;443</Citation><ArticleIdList><ArticleId IdType="pubmed">31507117</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews JA, Jackson CE, Heiman-Patterson TD et al (2020) Real-world evidence of riluzole effectiveness in treating amyotrophic lateral sclerosis. Amyotroph Lateral Scler Front Degener 21:509&#x2013;518. https://doi.org/10.1080/21678421.2020.1771734</Citation></Reference><Reference><Citation>Hesters A, del Amador MM, Debs R et al (2020) Predictive factors for prognosis after gastrostomy placement in routine non-invasive ventilation users ALS patients. Sci Rep 10:1&#x2013;6. https://doi.org/10.1038/s41598-020-70422-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-70422-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns TM, Graham CD, Rose MR, Simmons Z (2012) Quality of life and measures of quality of life in patients with neuromuscular disorders. Muscle Nerve 46:9&#x2013;25</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.23245</ArticleId></ArticleIdList></Reference><Reference><Citation>Ilse B, Prell T, Walther M, Hartung V, Penzlin S, Tietz F, Witte OW, Strauss B, Grosskreutz J (2014) Relationships between disease severity, social support and health-related quality of life in patients with amyotrophic lateral sclerosis. Soc Indic Res 120:871&#x2013;882. https://doi.org/10.1007/s11205-014-0621-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11205-014-0621-y</ArticleId></ArticleIdList></Reference><Reference><Citation>van Groenestijn AC, Kruitwagen-van Reenen ET, Visser-Meily JMA et al (2016) Associations between psychological factors and health-related quality of life and global quality of life in patients with ALS: a systematic review. Health Qual Life Outcomes 14:14. https://doi.org/10.1186/s12955-016-0507-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12955-016-0507-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh J, Kim JA (2017) Supportive care needs of patients with amyotrophic lateral sclerosis/motor neuron disease and their caregivers: a scoping review. J Clin Nurs 26:4129&#x2013;4152</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jocn.13945</ArticleId></ArticleIdList></Reference><Reference><Citation>Antoniadi AM, Galvin M, Heverin M, Hardiman O, Mooney C (2020) Prediction of caregiver burden in amyotrophic lateral sclerosis: a machine learning approach using random forests applied to a cohort study. BMJ Open 10:10. https://doi.org/10.1136/bmjopen-2019-033109</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2019-033109</ArticleId></ArticleIdList></Reference><Reference><Citation>Creemers H, De Mor&#xe9;e S, Veldink JH et al (2016) Factors related to caregiver strain in ALS: a longitudinal study. J Neurol Neurosurg Psychiatry 87:775&#x2013;781. https://doi.org/10.1136/jnnp-2015-311651</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2015-311651</ArticleId><ArticleId IdType="pubmed">26341327</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeber AA, Pols AJ, Hijdra A, Grupstra HF, Willems DL, de Visser M (2019) Advance care planning in progressive neurological diseases: lessons from ALS. BMC Palliat Care 18:50. https://doi.org/10.1186/s12904-019-0433-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12904-019-0433-6</ArticleId><ArticleId IdType="pubmed">31196046</ArticleId><ArticleId IdType="pmc">6567602</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogden A, Greenfield D, Nugus P, Kiernan MC (2012) What influences patient decision-making in amyotrophic lateral sclerosis multidisciplinary care? A study of patient perspectives. Patient Prefer Adherence 6:829. https://doi.org/10.2147/PPA.S37851</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/PPA.S37851</ArticleId><ArticleId IdType="pubmed">23226006</ArticleId><ArticleId IdType="pmc">3514070</ArticleId></ArticleIdList></Reference><Reference><Citation>Fullam T, Stephens HE, Felgoise SH, Blessinger JK, Walsh S, Simmons Z (2016) Compliance with recommendations made in a multidisciplinary ALS clinic. Amyotroph Lateral Scler Front Degener 17:30&#x2013;37. https://doi.org/10.3109/21678421.2015.1074703</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2015.1074703</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>